



## **ALPHA-1 FOUNDATION**

### **Public Policy Priorities**

**Research** – Advance Alpha-1 research conducted by the National Institutes of Health and other Federal Agencies, including promoting expansion of the Alpha-1 research portfolio and conducting scientific conferences and information dissemination.

**New Therapeutics** – Work with the U.S. Food and Drug Administration and other agencies to ensure that new therapies are available for the treatment of Alpha-1. Ensure expedited licensure and product availability.

**Targeted Screening and Detection** – Promote awareness and the recommendations of the *American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900*, to ensure effective targeted Alpha-1 screening and detection initiatives are implemented for the identification of Alpha-1 in population groups at risk, including family testing.

**Access to Care** – Support legislative and administrative proposals that ensure improved patient access to care. Improve health insurance benefits and reduce restrictions to public programs.

**Blood Product Safety** – Work closely with the U.S. Food and Drug Administration, Department of Health and Human Services, Congress, and other agencies where appropriate to promote policies that ensure the safety of blood products.

**Education, Outreach, and Awareness** – Work with the community to support education, outreach, and awareness.

#### Alpha-1 Foundation mission:

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.